(Q33503487)

27 July 2017

title

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study (English)

1 reference

27 July 2017

0 references

1 reference

1 reference

1 reference

2

Lokhorst HM

1 reference

27 July 2017

van Zaanen HC

1

1 reference

27 July 2017

Aarden LA

3

1 reference

27 July 2017

Rensink HJ

4

1 reference

27 July 2017

Warnaar SO

5

1 reference

27 July 2017

van der Lelie J

6

1 reference

27 July 2017

van Oers MH

7

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 August 1998

1 reference

British Journal of Haematology

27 July 2017

published in

1 reference

27 July 2017

volume

102

1 reference

27 July 2017

issue

3

1 reference

27 July 2017

page(s)

783-790

1 reference

Production of hybridoma growth factor by human monocytes.

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Interleukin 6 is essential for in vivo development of B lineage neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Response of interleukin‐6‐deficient mice to tumor necrosis factor‐induced metabolic changes and lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Osteoclast function in Paget's disease and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Interleukin-6, a new target for therapy in multiple myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Interleukin-6 dependence of advanced malignant plasma cell dyscrasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00835.X

10.1046/J.1365-2141.1998.00835.X

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference